Velesco Pharma Expands With the Opening of a New Laboratory
News Aug 05, 2016
Velesco Pharma has further expanded its capabilities for materials management by opening a new laboratory in its Plymouth, Mich., facility. The new laboratory will be largely utilized for the storage, dispensing, inventory management and distribution of non-GMP materials such as API, intermediates and compounds transitioning into development. This addition of increased compound management capacity and capabilities is in response to the needs of Velesco's expanding client base.
The company has analysis and formulation expertise to support this compound management activity. Complementing the current cGMP material storage and dispensing operation in Velesco’s Kalamazoo, Mich., facility, this new laboratory space enables Velesco to provide compound management services for materials with either cGMP or non-GMP requirements.
These services include long- and short-term storage of materials at ambient, refrigerated or frozen temperatures as well as material aliquoting over a wide weight range, along with labeling and distribution.
“Our newly expanded materials management laboratory is well suited to meet our client’s increasing need for the storage, analysis and the handling of compounds in the early stage of development,” said Dave Barnes, Ph.D., chief executive officer at Velesco. “We look forward to collaborating with our clients to efficiently provide the quality services to which they have become accustomed.”
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018